GlassScriptPhysician profile
Osama Sidhom
NPI 1649238148
$6,084.54
in general payments reported to CMS, 2019-2025
34 companies · $1,926 in 2025
The $1,926 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $247 · 2021: $717 · 2022: $430 · 2023: $882 · 2024: $1,129 · 2025: $1,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,937.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,956.97 | 2020-2025 | Skyrizi, Linzess, Rinvoq |
| Madrigal Pharmaceuticals | $431.03 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $400.94 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $231.90 | 2019-2024 | Xifaxan |
| Gilead Sciences, INC. | $221.09 | 2019-2025 | |
| Novo Nordisk INC | $201.33 | 2023-2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $197.49 | 2019-2021 | |
| Ardelyx, INC. | $160.99 | 2023-2025 | Ibsrela |
| Amgen INC. | $151.27 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $146.89 | 2019-2025 | |
| Celgene Corporation | $122.44 | 2021-2024 | Zeposia |
| Glaxosmithkline, LLC. | $114.38 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $80.67 | 2019-2023 | Dificid |
| Ipsen Biopharmaceuticals, INC | $67.22 | 2025 | Iqirvo |
| Genzyme Corporation | $62.71 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $59.76 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $56.33 | 2023-2024 | Andexxa |
| Allergan, INC. | $47.32 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $43.35 | 2023 | Zeposia |
| Shield Therapeutics INC | $33.35 | 2024 | |
| Celltrion USA INC. | $30.53 | 2024 | Vegzelma |
| Ferring Pharmaceuticals INC. | $26.93 | 2019-2020 | |
| Pfizer INC. | $26.31 | 2021-2024 | |
| Shionogi INC | $24.68 | 2019 | |
| Redhill Biopharma INC. | $24.00 | 2021 | |
| Albireo Pharma, INC. | $21.06 | 2024 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $19.59 | 2024 | Voquezna |
| Braintree Laboratories, INC. | $19.09 | 2024 | Suflave, Sutab |
| Exact Sciences Corporation | $19.08 | 2023 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $18.80 | 2023 | |
| Genentech, INC. | $18.68 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.91 | 2019 | |
| Aries Pharmaceuticals, INC. | $16.79 | 2019 | |
| Phadia US INC. | $14.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Osama Sidhom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.